News

AbstractPurposeSickle Cell Disease (SCD) is a monogenic, autosomal recessive disorder caused by mutations in the β-globin gene, resulting in the production of…

Higher blood levels of erythropoietin (EPO), a hormone that stimulates the production of red blood cells, increase the risk of blood clot-related, or thrombotic,…

Fulcrum Therapeutics has begun a strategic review that may result in it getting sold, a move made after the company’s main medicine hit a possibly insurmountable…

Fulcrum Therapeutics said today it is scrapping its lead pipeline program to develop pociredir as a treatment for sickle cell disease (SCD) and launching a “…

SummaryQuestionThis study analyzed the cost-effectiveness of three treatment strategies for sickle cell disease (SCD): standard care (SOC), gene therapy (GT), and…

June 2 (Reuters) - Shares of Fulcrum Therapeutics (FULC.O), opens new tab plunged 52% on Tuesday after the company said it would abandon development ​of its…

CorrectSequence Therapeutics Reports Positive 15-Month Follow-Up Data for CS-206SHANGHAI, June 2, 2026 /PRNewswire/ -- CorrectSequence Therapeutics Co., Ltd. (…

The drug, pociredir, was being developed as an ​oral treatment for sickle-cell disease, an inherited blood disorder that can cause ​pain, anemia, organ damage and…

AbstractRenin-angiotensin-aldosterone system inhibitors (RAASi) are suggested for treating albuminuria in patients with sickle cell disease (SCD). RAASi may…

AbstractSickle cell disease (SCD) is a globally prevalent inherited hemoglobinopathy marked by chronic hemolysis, vaso-occlusion, and systemic inflammation, leading…